ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Hanall Biopharma (009420.KO)
Hanall Biopharma stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Korea Exchange (KOSPI) · South Korea
₩38,550▼ -4.10%
Prices as of Oct 26, 2026 · KRW
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Hanall Biopharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Hanall Biopharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Hanall Biopharma a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩33,510 and ₩42,964; in 9 out of 10, between ₩26,884 and ₩53,553. Estimated annual volatility is 72%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩2.1T
- Market cap (USD)
- $1.5B
- 52-week high
- ₩73,000
- 52-week low
- ₩33,450
- Revenue (12 months)
- ₩163B
- Gross margin
- 52.7%
- Operating margin
- 12.3%
- Net margin
- -15.3%
- Beta
- 0.93
What this means
ATLAS does not publish a fair value for 009420.KO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 009420.KO has traded between ₩33,450 and ₩73,000. Today it is 47.2% below that high and 15% above its low.
Its beta is 0.93: it moves roughly in line with the market.
About the company
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally.
Want to see everything about Hanall Biopharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Hanall Biopharma do?
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally.
What is the chance 009420.KO goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, 009420.KO ends the month between ₩33,510 and ₩42,964.
How big is Hanall Biopharma and what is its P/E ratio?
Hanall Biopharma's market capitalization is ₩2.1T. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 009420.KO?
ATLAS estimates annual volatility at 72%. In a typical month, half of the outcomes end between ₩33,510 and ₩42,964.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer